Author,Affiliation,Article Title
Yanqiong Shen,"RNAlfa Biotech, Hefei 230088, China.",Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.
Krishna Mohan Vadrevu,"Bharat Biotech International Limited, Hyderabad, India. Electronic address: kmohan@bharatbiotech.com.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Brunda Ganneru,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Siddharth Reddy,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Bhargav Reddy,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Badri Patnaik,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Sai D Prasad,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Raches Ella,"Bharat Biotech International Limited, Hyderabad, India.","A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™."
Quanyi Yin,"Department of Research & Development, Yither Biotech Co. Ltd, Shanghai, China.","Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice."
Shuoyao Song,"Department of Research & Development, Yither Biotech Co. Ltd, Shanghai, China.","Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice."
Zhilei Liu,"Department of Research & Development, Yither Biotech Co. Ltd, Shanghai, China.","Novel nanoemulsion adjuvant stabilized by TPGS possesses equivalent physicochemical properties, Turbiscan stability, and adjuvanticity to AS03 for eliciting robust immunogenicity of subunit vaccines in mice."
Pan-Xue Wu,"State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.",African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.
Xu-Guang Du,"State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.",African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.
Yao-Feng Zhao,"State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.",African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.
Sen Wu,"State Key Laboratory of Animal Biotech Breeding College of Biological Sciences, National Engineering Laboratory for Animal Breeding, Frontiers Science Center for Molecular Design Breeding, China Agricultural University, Beijing, China.",African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly.
Omolbani Kheirkhah,"Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.",Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.
Sakineh Pirahmadi,"Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.",Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.
Akram Abouie Mehrizi,"Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran.",Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.
Abbasali Raz,"Malaria and Vector Research Group (MVRG), Biotechnology Research Center (BRC), Pasteur Institute of Iran, Tehran, Iran. Electronic address: raz.biotech@gmail.com.",Population genetic structure of the fibrinogen-related protein 1 (FREP1) in Iranian isolates of Anopheles stephensi as a promising mosquito-based malaria vaccine candidate.
Fangqin Xie,"Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Kaili Du,"Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Junrong Li,"Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Sumei Zhong,"Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Chun Fan,"Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Qiufen Zhang,"Xiamen Innovax Biotech Co., Ltd., Xiamen 361000, Fujian, China.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Dongjuan Zhang,"Vaccine Clinical Trial Center, Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012, Fujian, China. Electronic address: dongj8888@163.com.",Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Xiaoyu Xu,"Vazyme Biotech Co. Ltd, 210000, Nanjing, China.",Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.
Lingjie Xu,"Vazyme Biotech Co. Ltd, 210000, Nanjing, China.",Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.
Fengze Wang,"Vazyme Biotech Co. Ltd, 210000, Nanjing, China.",Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.
Yingping Chen,"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.",Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.
Bo Xing,"Department of Immunization Program, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.",Establishing a universal IVRP method for quadrivalent HPV vaccines to replace in vivo potency tests.
Christian Garde,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark. cg@evaxion.ai.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Michail A Pavlidis,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Pablo Garces,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Emma J Lange,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Stine Friis,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Daniela Kleine-Kohlbrecher,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Jens V Kringelum,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Birgitte Rønø,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Thomas Trolle,"Evaxion Biotech A/S, Dr Neergaards Vej 5F, Hørsholm, Denmark.",Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines.
Sadaf Parveen,"Malaria Biology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Pragyan Parimita Rath,"Parasite Cell Biology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Sheenam Verma,"Structural Immunology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India; Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd milestone, Faridabad, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Shahnawaz Ahmad,"Translational Bioinformatics Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Iqbal Taliy Junaid,"Malaria Biology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Dhiraj Kumar,"Cellular Immunology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Dinesh Gupta,"Translational Bioinformatics Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Asif Mohmmed,"Parasite Cell Biology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Dinakar M Salunke,"Structural Immunology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India. Electronic address: dinkar.salunke55@gmail.com.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Pawan Malhotra,"Malaria Biology Group, International Centre for Genetic Engineering & Biotechnology (ICGEB), New Delhi, India. Electronic address: pawanmal@gmail.com.","Novel, fully human, anti-PfCSP antibodies with potent antimalarial activity using a phage display based strategy."
Rochelle P Walensky,"Bayer Fellow in Health & Biotech, American Academy in Berlin, Berlin, Germany.",Revising US MMR Vaccine Recommendations Amid Changing Domestic Risks.
Longxu Xie,"Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.","Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases."
Song Qiu,"Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.","Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases."
Aijuan Xu,"Hybribio Medical Laboratory Group Ltd., Chaozhou, Guangdong, China.","Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases."
Yingmu Cai,"Joint Laboratory of Shantou University Medical College and Guangdong Hybribio Biotech Ltd., Shantou University Medical College, Shantou, Guangdong, China. yingmucai@hybribio.cn.","Prevalence, trends, and geographic distribution of human papillomavirus infection in Chinese women: a summative analysis of 2,728,321 cases."
Xuanxuan Zhang,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Yulong Fu,"School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Guanxing Liu,"Changchun Institute of Biological Products Co., Ltd., Changchun, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Ying Wang,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Qian He,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Na Li,"Beijing Minhai Biotechnology Co., Ltd., Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Junzhi Wang,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Zhenglun Liang,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Miao Xu,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Qunying Mao,"State Key Laboratory of Drug Regulatory Science, Evaluation of Biological Products, Key Laboratory of Research on Quality and Standardization of Biotech Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.",Exploring the standardization of human nasal antibody measurements.
Bin Wang,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Quanyi Yin,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Li Yi,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Caixia Su,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Yang Wen,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Man Qiao,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Yingchen Ju,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Zhihua Liu,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Yelin Xiong,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Zhilei Liu,"Department of Research & Development, Yither Biotech Co Ltd, Shanghai, China.",Lyophilized monkeypox mRNA lipid nanoparticle vaccines with long-term stability and robust immune responses in mice.
Juan Liu,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: liuj@zhejianghaichang.com.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Xicheng Chen,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Chuanqian Chen,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Jie Wu,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Fengyang Xie,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Jing Li,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Huafeng Han,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Yingying Zhao,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Yongsheng Yang,"Nucleic Acid Medicine Innovation Center, Zhejiang Haichang Biotech Co., Ltd., Hangzhou, Zhejiang 310020, China. Electronic address: yongsheng.yang@thewogroup.com.",Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat.
Yabin Tian,"Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.","Corrigendum to ""Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway"" [Virus Research 228 (2017) 102-108]."
Weijin Huang,"Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.","Corrigendum to ""Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway"" [Virus Research 228 (2017) 102-108]."
Zhiheng Wen,"Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.","Corrigendum to ""Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway"" [Virus Research 228 (2017) 102-108]."
Chenyan Zhao,"Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China.","Corrigendum to ""Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway"" [Virus Research 228 (2017) 102-108]."
Youchun Wang,"Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, Division of HIV/AIDS and Sexually Transmitted Virus Vaccines, National Institutes for Food and Drug Control, No. 2 Tiantanxili, Beijing 100050, China. Electronic address: wangyc@nifdc.org.cn.","Corrigendum to ""Systematic identification of HEV ORF2 interactome reveals that TMEM134 engages in ORF2-mediated NF-κB pathway"" [Virus Research 228 (2017) 102-108]."
M S von Elling-Tammen,"Research Group Medical Biotechnology & Bioengineering, Faculty of Applied Natural Sciences, TH Köln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany; Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Göttingen, Germany.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
F Taft,"Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Göttingen, Germany.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
V Thom,"Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Göttingen, Germany.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
J Stitz,"Research Group Medical Biotechnology & Bioengineering, Faculty of Applied Natural Sciences, TH Köln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
S Barbe,"Research Group Medical Biotechnology & Bioengineering, Faculty of Applied Natural Sciences, TH Köln - University of Applied Sciences, Campusplatz 1, 51379 Leverkusen, Germany. Electronic address: stephan.barbe@th-koeln.de.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
A Krause,"Sartorius Stedim Biotech GmbH, August-Spindler-Straße 11, 37079 Göttingen, Germany.",Optimizing nuclease treatment to enhance anion exchange chromatography of HIV-derived virus-like particles.
Ruizhi Wang,"Qingdao Vland Biotech INC., Qingdao, 266102, China.",Immunogenic cross-reactivity between different serotypes novel duck reoviruses: Evaluation of cross-protection provided by mono or bivalent vaccine.
Sijia Liu,"Qingdao Vland Biotech INC., Qingdao, 266102, China.",Immunogenic cross-reactivity between different serotypes novel duck reoviruses: Evaluation of cross-protection provided by mono or bivalent vaccine.
Zhe Lv,"Sinovac Biotech Ltd., Beijing, China.",CVA16 infection causes neurological injury by engaging TLR2/MYD88/TNF-α/CXCL1 signalling pathway in hSCARB2 knock-in mice.
Fu-Ying Shih,"Ph.D. Program for Biotech Pharmaceutical Industry, China Medical University, Taichung, Taiwan, ROC.",Hypoxic tumor cell line lysate-pulsed dendritic cell vaccine exhibits better therapeutic effects on hepatocellular carcinoma.
Fangyuan Zheng,"R&D Department, Vazyme Biotech Co., Ltd, Nanjing, China.",Constructions and immunogenicity evaluations of two porcine epdemic diarrhea virus-like particle vaccines.
Peifen Gao,"National Vaccine & Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China.",Extracellular vesicles and bioactive peptides for regenerative medicine in cosmetology.
Yinan Wang,"National Vaccine & Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China.",Extracellular vesicles and bioactive peptides for regenerative medicine in cosmetology.
Wenlin An,"National Vaccine & Serum Institute, China National Biotech Group, Sinopharm Group, Beijing 101111, China. Electronic address: anwenlin@sinopharm.com.",Extracellular vesicles and bioactive peptides for regenerative medicine in cosmetology.
Thorkell Gudjónsson,"Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.","Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patients."
Peiquan Huang,"Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.","Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patients."
Claus S Sørensen,"Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.","Replication stress, microcephalic primordial dwarfism, and compromised immunity in ATRIP deficient patients."
Ernesto T A Marques,"Department of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Department of Virology and Experimental Therapeutics, Oswaldo Cruz Foundation (Fiocruz), Recife, Brazil.",Zika virus: advancing a priority research agenda for preparedness and response.
Josephine P Golding,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus: advancing a priority research agenda for preparedness and response.
Petra C Fay,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus: advancing a priority research agenda for preparedness and response.
Ana Cehovin,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus: advancing a priority research agenda for preparedness and response.
Ana Cehovin,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.
Petra C Fay,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.
Josephine P Golding,"Infectious Disease Strategic Programme, Wellcome Trust, London, UK.",Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development.
Steven Thomas,"Biometrics, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA; Chiesi USA, Cary, NC, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Anastasia A Aksyuk,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Lindsay E Clegg,"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Alexander Currie,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Haitao Yang,"Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Karin Flyrin,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Mölndal, Sweden.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Michael Gibbs,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Cambridge, UK.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
John L Perez,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Lee-Jah Chang,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Taylor S Cohen,"Vaccines & Immune Therapies, BioPharmaceuticals Research & Development, AstraZeneca, Gaithersburg, MD, USA. Electronic address: taylor.cohen@astrazeneca.com.","Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial."
Jiazheng Wei,"College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.",RNA vaccines: The dawn of a new age for tuberculosis?
Chongyang Wu,"Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Xi Wang,"Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Yu Zhou,"Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Xinshuo Zhu,"Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Yu Ma,"Bacterial Vaccine Manufacturing Facility, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Wenming Wei,"Department of Research and Development, Beijing Institute of Biological Products Co., Ltd., Beijing 100176, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Yuntao Zhang,"China National Biotec Group Co., Ltd., Beijing 100024, China.",Development and Implementation of a Single Radial Diffusion Technique for Quality Control of Acellular Pertussis Vaccines.
Hai-Lung Dai,"DiaVac Biotech Company, Doylestown, PA, USA.",SARS-CoV-2 neutralizing antibody determination after vaccination using spectrophotometric measurement of lateral flow immunochromatography.
Jie Gao,"Beijing Zhonghai Biotech Co., Ltd., Beijing 100081, China.",Impact of foot-and-mouth disease virus on memory T and B cell populations in swine.
Dongdong Liu,"Inner Mongolia Bigvet Biotech Co., Ltd., Inner Mongolia 011500, China.",Impact of foot-and-mouth disease virus on memory T and B cell populations in swine.
Guohua Wang,"Inner Mongolia Bigvet Biotech Co., Ltd., Inner Mongolia 011500, China.",Impact of foot-and-mouth disease virus on memory T and B cell populations in swine.
Tijana Krnjeta Janicijevic,"F. Hoffmann - La Roche Ltd., Basel, Switzerland.",Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
R Frank Cornell,"AbbVie, Inc, North Chicago, Illinois, USA.",Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer.
Nagendra Singh,"School of Biotechnology, Gautam Buddha University, Greater Noida, India",Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus.
Shopnil Akash,"Computational Biology Research Laboratory, Department of Pharmacy, Daffodil International University, Dhaka,
Bangladesh",Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus.
Yousef A Bin Jardan,"Department of Pharmaceutics, College of Pharmacy, King Saud University, PO Box, Riyadh, 11451, Saudi Arabia",Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus.
Mohammed Bourhia,"Swalife Biotech Ltd, Unit 3D, North Point House, North Point Business Park, Cork, Ireland",Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus.
Maroudam Veerasami,"CisGen Biotech Discoveries Pvt Ltd, Chennai, India.",Comparative performance of tuberculin and defined-antigen cocktails for detecting bovine tuberculosis in BCG-vaccinated cattle in natural settings.
Byung Ha Lee,"NeoImmuneTech Inc, Rockville, Maryland, USA.",Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
Li-Lian Kwok,"Cytel (Shanghai) Co Ltd, Shanghai, China.",Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.
